Kiran Mazumdar-Shaw is nothing if not innovative.
Starting with a postgraduate degree in brewing from an Australian university, she built the largest biopharmaceutical company in India.
And, along the way, she dispensed with antagonistic unionists by automating her production line; developed and patented a solid substrate bioreactor that facilitated the cultivation and extraction of microorganisms used in the production of industrial enzymes; skirted around international patents with a revolutionary method for manufacturing human insulin in yeast; created new therapies for both psoriasis and cancer of the head and neck; and established a micro-insurance program that has the potential to provide quality health care and medicines to millions of Indian villagers for an annual fee of just $3 per head.
"The difference lies in our DNA"
@joseph11345 @BBMPCOMM Yes that will happen by April 2019— Kiran Mazumdar Shaw (@kiranshaw) November 20, 2018
Just spent 2 hours with @BBMPCOMM and his team to understand all the ongoing development work on mobility n SWM and… https://t.co/y5iLbOCWqx— Kiran Mazumdar Shaw (@kiranshaw) November 20, 2018